Background Pneumoconiosis is a chronic inflammatory disease that cannot be completely cured. Therefore, how to control lung inflammation and delay of the body aging is one of the keys to treating pneumoconiosis. The studies in past two decades suggested that many small molecule drugs are able to enhance cardiopulmonary function. Objective To explore the effects of homeopathic dosing and combined dosing of β-nicotinamide mononucleotide and taurine on experimental silicosis in rats. Methods Seventy-two SD specific pathogen-free rats were randomized into 4 groups (18 mice in each group): negative control group (ultrapure water, without dust), positive control group, homeopathic treatment group, co-administered treatment group. One mL of quartz dust suspension was injected into the rat trachea by disposable non-exposed tracheal injection method (50 mg·mL⁻¹) to establish a rat silicosis model. Rats were administered by gavage since the 4th day after dust exposure. The homeopathic treatment group rats received taurine solution (0.03 g·mL⁻¹) in the morning and β-nicotinamide mononucleotide (0.03 g·mL⁻¹) in the afternoon; the co-administered treatment group rats received a mixed solution (0.015 g·mL⁻¹ β-nicotinamide mononucleotide + 0.015 g·mL⁻¹ taurine) twice, in the morning and afternoon respectively. The positive and negative control groups received equivalent of ultrapure water in the morning and afternoon. All groups of rats were administered 5 d a week for a total of 6 weeks. The rats were neutralized after 6 weeks of administration. Organ coefficient, lung hydroxyproline content, whole lung dry and wet weights, whole lung free silica content, and cell count and classification in lung lavage fluid were measured and calculated, and lung histopathological changes in lung samples were observed. Results Compared with the positive control group, the whole lung wet weight, whole lung dry weight , total cell count, neutrophil rate, lung organ coefficient, lung hydroxyproline content, and whole lung free silica content were reduce in the homeopathic treatment group, and the co-administered treatment group (P＜0.05). Compared with the negative control group, the total cell count, neutrophil rate, lung organ coefficient, lung hydroxyproline content, and whole lung free silica content were elevated in the homeopathic treatment group and the co-administered treatment group, the whole lung dry weight was elevated in the co-administered treatment group, and those differences were all statistically significant (P＜0.05). The rat lung histopathological results showed that, in the positive control group, round or oval nodules were formed in the lung tissue, which were phagocytic cellular nodules, and the alveolar structures in some areas still existed. The histopathological changes in the homeopathic treatment group and the co-administered treatment group were similar to those of the positive group, but less severe. No pathological change was observed in the lung tissue of the negative control group. Conclusion Some improvement and dust removal in experimental silicosis rats by homeopathic dosing and combined dosing of β-nicotinamide mononucleotide and taurine are observed.

Autologous blood donation is an important strategy of blood conservation. The Administrative Measures for the Clinical Use of Blood in Medical Institutions (Order No. 85 of the National Health Commission) requires medical institutions to promote the implementation of autologous blood donation actively. The clinical practice guidelines for patient blood management also recommend the proactive use of autologous blood donation to reduce the reliance on allogeneic blood. Preoperative autologous blood donation (PABD) is one of the autologous blood donation with wide range of indications, easy to operate, and can effectively reduce the transfusion of allogeneic blood. However, the performance of PABD in China is unsatisfactory due to various factors such as the patient composition of medical institutions, the implementation of outpatient department of blood transfusion, the level of attention paid to this issue, and the fact that traditional PABD do not meet clinical requirements. Therefore, improving the PABD model and exploring new PABD technology, as well as promoting their clinical application, are critical measures to meet the development requirements of patient blood management and to alleviate the shortage of blood supply. This article summarizes the improvements in the PABD model, and a novel PABD technology of PABD—preoperative deep apheresis of autologous red blood cells and/or platelets (deep apheresis autologous blood storage technology), and the current situation of clinical application of PABD to provide paradigm for clinical transfusion.

Acetaminophen (APAP) is the primary cause of drug-induced acute liver failure. Ovarian tumor deubiquitinase 6A (OTUD6A), a recently discovered deubiquitinase of the OTU family, has been primarily studied in tumor contexts. However, its role in APAP-induced liver injury (AILI) remains unclear. Therefore, this study aimed to investigate the involvement of OTUD6A in the pathogenesis of AILI. Our findings demonstrated a substantial upregulation of OTUD6A in both the liver tissue and isolated hepatocytes of mice following APAP stimulation. OTUD6A knockout exacerbated APAP-induced inflammation, hepatocyte necrosis, and liver injury, whereas OTUD6A overexpression alleviated these pathologies. Mechanistically, OTUD6A directly interacted with the enhancer of zeste homolog 2 (EZH2) and selectively removed K48-linked polyubiquitin chains from EZH2, enhancing its stability. This resulted in increased protein levels of EZH2 and H3K27me3, as well as reduced endoplasmic reticulum (ER) stress and cell death in hepatocytes. Collectively, our research uncovers a novel role for OTUD6A in mitigating APAP-induced liver injury by promoting EZH2 stabilization.

Objective To investigate the effect of ergothioneine(EGT)on tissue metabolism in middle-aged and aged mice.Methods Nine-month-old middle-aged and aged C57BL/6J mice were selected to be gavaged with EGT aqueous solution at the dose and frequency of 35 mg EGT per kg body weight every two days.The control group was gavaged with the same amount of water.Both groups were fed with EGT-free diet.After 7 weeks,the liver,kidney,and small intestine of mice were collected,and untargeted metabolomics analysis was performed using ultra-per-formance liquid chromatography-mass spectrometry(UHPLC-MS).The differential metabolites were selected for KEGG metabolic pathway enrichment analysis.Results Compared with the control group,the abundances of me-tabolites related to redox balance in liver,kidney and small intestine of middle-aged and aged mice treated with EGT did not change significantly.However,taurine and hypotaurine metabolism in liver(P＜0.01),purine metabo-lism in kidney(P＜0.01),and cysteine and methionine metabolism in small intestine(P＜0.001)were affected.Conclusions Non-redox-related metabolic changes in the liver,kidney and small intestine of middle-aged and aged mice by ergothioheine.

Attracting overseas medical consumption is the driving force behind the development of the medical industry in China's current"dual circulation"new development pattern.The progress of domestic medical technology and the improvement of service quality,the development of the economy and society,the enhancement of residents'health awareness,the increase of government investment in the health field,the advantages of the medical market and price competition,the guidance and support of government policies,international medical exchanges and cooperation,and the improvement of the medical insurance system are the main driving factors for attracting overseas medical consumption.Improving the level of medical technology,stimulating the vitality of attracting medical consumption,increasing the supply of medical consumption,unleashing the potential of attracting medical consumption,improving the quality of medical services,building support for attracting medical consumption to return,optimizing the medical consumption environment,creating an atmosphere for attracting medical consumption,and regulating overseas medical consumption,injecting the momentum of attracting medical consumption to return are the main implementation ways to attract overseas medical consumption to return.

Attracting overseas medical consumption is the driving force behind the development of the medical industry in China's current"dual circulation"new development pattern.The progress of domestic medical technology and the improvement of service quality,the development of the economy and society,the enhancement of residents'health awareness,the increase of government investment in the health field,the advantages of the medical market and price competition,the guidance and support of government policies,international medical exchanges and cooperation,and the improvement of the medical insurance system are the main driving factors for attracting overseas medical consumption.Improving the level of medical technology,stimulating the vitality of attracting medical consumption,increasing the supply of medical consumption,unleashing the potential of attracting medical consumption,improving the quality of medical services,building support for attracting medical consumption to return,optimizing the medical consumption environment,creating an atmosphere for attracting medical consumption,and regulating overseas medical consumption,injecting the momentum of attracting medical consumption to return are the main implementation ways to attract overseas medical consumption to return.

Attracting overseas medical consumption is the driving force behind the development of the medical industry in China's current"dual circulation"new development pattern.The progress of domestic medical technology and the improvement of service quality,the development of the economy and society,the enhancement of residents'health awareness,the increase of government investment in the health field,the advantages of the medical market and price competition,the guidance and support of government policies,international medical exchanges and cooperation,and the improvement of the medical insurance system are the main driving factors for attracting overseas medical consumption.Improving the level of medical technology,stimulating the vitality of attracting medical consumption,increasing the supply of medical consumption,unleashing the potential of attracting medical consumption,improving the quality of medical services,building support for attracting medical consumption to return,optimizing the medical consumption environment,creating an atmosphere for attracting medical consumption,and regulating overseas medical consumption,injecting the momentum of attracting medical consumption to return are the main implementation ways to attract overseas medical consumption to return.

Attracting overseas medical consumption is the driving force behind the development of the medical industry in China's current"dual circulation"new development pattern.The progress of domestic medical technology and the improvement of service quality,the development of the economy and society,the enhancement of residents'health awareness,the increase of government investment in the health field,the advantages of the medical market and price competition,the guidance and support of government policies,international medical exchanges and cooperation,and the improvement of the medical insurance system are the main driving factors for attracting overseas medical consumption.Improving the level of medical technology,stimulating the vitality of attracting medical consumption,increasing the supply of medical consumption,unleashing the potential of attracting medical consumption,improving the quality of medical services,building support for attracting medical consumption to return,optimizing the medical consumption environment,creating an atmosphere for attracting medical consumption,and regulating overseas medical consumption,injecting the momentum of attracting medical consumption to return are the main implementation ways to attract overseas medical consumption to return.

Attracting overseas medical consumption is the driving force behind the development of the medical industry in China's current"dual circulation"new development pattern.The progress of domestic medical technology and the improvement of service quality,the development of the economy and society,the enhancement of residents'health awareness,the increase of government investment in the health field,the advantages of the medical market and price competition,the guidance and support of government policies,international medical exchanges and cooperation,and the improvement of the medical insurance system are the main driving factors for attracting overseas medical consumption.Improving the level of medical technology,stimulating the vitality of attracting medical consumption,increasing the supply of medical consumption,unleashing the potential of attracting medical consumption,improving the quality of medical services,building support for attracting medical consumption to return,optimizing the medical consumption environment,creating an atmosphere for attracting medical consumption,and regulating overseas medical consumption,injecting the momentum of attracting medical consumption to return are the main implementation ways to attract overseas medical consumption to return.

Attracting overseas medical consumption is the driving force behind the development of the medical industry in China's current"dual circulation"new development pattern.The progress of domestic medical technology and the improvement of service quality,the development of the economy and society,the enhancement of residents'health awareness,the increase of government investment in the health field,the advantages of the medical market and price competition,the guidance and support of government policies,international medical exchanges and cooperation,and the improvement of the medical insurance system are the main driving factors for attracting overseas medical consumption.Improving the level of medical technology,stimulating the vitality of attracting medical consumption,increasing the supply of medical consumption,unleashing the potential of attracting medical consumption,improving the quality of medical services,building support for attracting medical consumption to return,optimizing the medical consumption environment,creating an atmosphere for attracting medical consumption,and regulating overseas medical consumption,injecting the momentum of attracting medical consumption to return are the main implementation ways to attract overseas medical consumption to return.